Heparin

Generic Name: Heparin

Brand Names: Heparin Leo

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: T2410KM04A

Background: Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...

Indication: Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...

Associated Conditions: Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein

Associated Therapies: Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Clinical Trials

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

Phase 2

Completed

Conditions: COVID-19
Pneumonia

Interventions: Drug: Heparin

First Posted Date: 2020-05-04

Last Posted Date: 2021-07-27

Lead Sponsor: University of Manitoba

Target Recruit Count: 1200

Registration Number: NCT04372589

Locations: 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇧🇷
AngioCor Blumenau, Blumenau, Santa Catarina, Brazil
🇧🇷
Centro de Pesquisas Clínicas Humap - UFMS, Campo Grande, Mato Grosso Do Sul, Brazil

and more 57 locations

Effects of Different Concentrations of Pressurized-heparin Flushing Fluid on Coagulation and Platelet Function Monitored by the Sonoclot Analyzer

Not Applicable

Completed

Conditions: Perioperative
Heparin

Interventions: Drug: Heparin
Drug: normal saline

First Posted Date: 2020-04-21

Last Posted Date: 2020-04-21

Lead Sponsor: Yangzhou University

Target Recruit Count: 60

Registration Number: NCT04355273

Locations: 🇨🇳
the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China

Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

Not Applicable

Recruiting

Conditions: Lipoprotein Lipase Deficiency

Interventions: Dietary Supplement: liquid meal
Drug: Heparin

First Posted Date: 2020-01-14

Last Posted Date: 2024-12-09

Lead Sponsor: Université de Sherbrooke

Target Recruit Count: 16

Registration Number: NCT04227678

Locations: 🇨🇦
Centre de recherche du CHUS, Sherbrooke, Quebec, Canada

Multi-center Application of Bivalirudin in Left Atrial Appendage Occlusion

Phase 4

Conditions: Evaluate the Safety and Efficacy of Bivalirudin in Decreasing Bleeding Risk

Interventions: Drug: Heparin
Drug: Bivalirudin

First Posted Date: 2019-12-12

Last Posted Date: 2019-12-12

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 100

Registration Number: NCT04195997

Locations: 🇨🇳
Zhongshan Hopital of Fudan University, Shanghai, Shanghai, China

Bivalirudin in Late PCI for Oatients With STEMI

Phase 4

Conditions: STEMI - ST Elevation Myocardial Infarction

Interventions: Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2019-12-04

Last Posted Date: 2019-12-10

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 1200

Registration Number: NCT04185077

Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation

Not Applicable

Conditions: Stroke of Basilar Artery
Optical Coherence Tomography
Antithrombotics
Endovascular Thrombectomy

Interventions: Drug: Unfractionated heparin
Drug: Acetylsalicylic Acid (ASA)

First Posted Date: 2019-10-10

Last Posted Date: 2019-10-17

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 25

Registration Number: NCT04121611

Locations: 🇨🇦
Sunnybrook Heath Sciences Center, Toronto, Ontario, Canada

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Withdrawn

Conditions: Chronic Total Occlusion
Atherosclerosis
Coronary Artery Disease
Peripheral Artery Disease

Interventions: Device: Roxwood Anchoring Catheters
Drug: Acetylsalicylic Acid
Drug: Heparin

First Posted Date: 2019-08-16

Last Posted Date: 2021-07-21

Lead Sponsor: Boston Scientific Corporation

Registration Number: NCT04059536

Locations: 🇺🇸
Cardiovascular Research of North Florida LLC, Gainesville, Florida, United States
🇺🇸
St. Mary Medical Center, Inc., Hobart, Indiana, United States
🇺🇸
Ascension St. John Hospital, Detroit, Michigan, United States

and more 7 locations